3-氨基-n-(4-氯苯基)苯甲酰胺 | 115175-17-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基-n-(4-氯苯基)苯甲酰胺
• 英文名称: N-(4'-chlorophenyl)-3-aminobenzamide
• 英文别名: 3-amino-N-(4-chlorophenyl)benzamide
• CAS: 115175-17-2
• 化学式: C₁₃H₁₁ClN₂O
• mdl: MFCD01112158
• 分子量: 246.696
• InChiKey: PFLYFNYASPUBRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  3-氨基-n-(4-氯苯基)苯甲酰胺 在 三光气 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 29.0h， 生成 N-(4-chlorophenyl)-3-[[9-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)anilino]purin-8-yl]amino]benzamide
  参考文献：
  名称：

  Structural Optimization and Structure–Activity Relationships of N²-(4-(4-Methylpiperazin-1-yl)phenyl)-N⁸-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations

  摘要：

  This paper describe the structural optimization of a hit compound, N-2-(4-(4-methylpiperazin-1-yl)phenyl)-N-8-phenyl-9H-purine-2,8-diamine (1), which is a reversible kinase inhibitor targeting both EGFR-activating and drug-resistance (T790M) mutations but has poor binding affinity. Structure-activity relationship studies led to the identification of 9-cyclopentyl-N-2-(4-(4-methylpiperazin-1-yl)phenyl)-N-8-phenyl-9H-purine-2,8-diamine (9e) that exhibits significant in vitro antitumor potency against the non-small-cell lung cancer (NSCLC) cell lines HCC827 and H1975, which harbor EGFR-activating and drug-resistance mutations, respectively. Compound 9e was further assessed for potency and selectivity in enzymatic assays and in vivo anti-NSCLC studies. The results indicated that compound 9e is a highly potent kinase inhibitor against both EGFR-activating and resistance mutations and has good kinase spectrum selectivity across the kinome. In vivo, oral administration of compound 9e at a dose of 5 mg/kg caused rapid and complete tumor regression in a HCC827 xenograft model, and an oral dose of 50 mg/kg initiated a considerable antitumor effect in an H1975 xenograft model.

  DOI：

  10.1021/jm301365e
• 作为产物：
  描述：

  N-(4-chlorophenyl)-3-nitrobenzamide 在 铁粉 、 氯化铵 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 以82.4%的产率得到3-氨基-n-(4-氯苯基)苯甲酰胺
  参考文献：
  名称：

  发现含有脲部分的苯甲酰胺衍生物作为可溶性环氧化物水解酶抑制剂

  摘要：

  通过抑制可溶性环氧化物水解酶 (sEH) 提高环氧脂肪酸可有效治疗炎症和疼痛相关疾病。在此，我们报道了一系列含有尿素部分的苯甲酰胺衍生物作为 sEH 抑制剂的发现。密集的结构修饰导致化合物A34被鉴定为具有良好物理化学性质的有效 sEH 抑制剂。分子对接揭示了独特的酰胺支架和 Phe497 之间的额外氢键相互作用，有助于增强 sEH 抑制效力。化合物A34对人 sEH 表现出出色的抑制活性，IC 50值为 0.04 ± 0.01 nM，K i值为 0.2 ± 0.1 nM。它还在体内代谢研究中显示出适度的全身药物暴露和口服生物利用度。在角叉菜胶诱导的炎性疼痛大鼠模型中，与t -AUCB和塞来昔布相比，化合物A34表现出更好的治疗效果。体内代谢研究和炎症性疼痛评估表明，A34可能是开发高效 sEH 抑制剂的可行先导化合物。

  DOI：

  10.1016/j.bioorg.2022.105898

文献信息

• Inhibitors of human glycogen phosphorylase
  申请人：Pfizer Products Inc.

  公开号：EP0978279A1

  公开（公告）日：2000-02-09

  The present invention is directed to a novel binding site for a glycogen phosphorylase inhibitor found within a glycogen phosphorylase enzyme. The novel binding site allows the design novel of glycogen phosphorylase inhibitors.

  本发明涉及一种在糖原磷酸化酶酶内发现的新型糖原磷酸化酶抑制剂结合位点。该新型结合位点使得能够设计新型的糖原磷酸化酶抑制剂。
• Use of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20030004162A1

  公开（公告）日：2003-01-02

  The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

  本发明提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用有效量的糖原磷酸化酶抑制剂；有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。本发明还提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用包含有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂的药物组合物；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。
• Glycogen phosphorylase inhibitors
  申请人：Pfizer Inc

  公开号：US05998463A1

  公开（公告）日：1999-12-07

  This invention relates to certain 5-acyl-2-oxo-indole-3-carboxamides useful as inhibitors of glycogen phosphorylase, methods of treating glycogen phosphorylase dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such compounds. This invention also relates to pharmaceutical compositions comprising those 5-acyl-2-oxo-indole-3-carboxamides in combination with antidiabetes agents and methods of treating glycogen phosphorylase dependent diseases or conditions with such compositions.

  这项发明涉及某些5-酰基-2-氧代吲哚-3-甲酰胺，它们作为糖原磷酸化酶的抑制剂是有用的，涉及使用这些化合物治疗糖原磷酸化酶依赖性疾病或病症的方法，以及包含这些化合物的药物组合物。该发明还涉及包含那些5-酰基-2-氧代吲哚-3-甲酰胺与抗糖尿病剂组合的药物组合物，以及使用这些组合物治疗糖原磷酸化酶依赖性疾病或病症的方法。
• Substituted triazinyl amide derivatives and methods of use
  申请人：——

  公开号：US20030087908A1

  公开（公告）日：2003-05-08

  The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer and angiogenesis-related disease.

  本发明包括化合物、类似物、前药及其药物可接受的盐，药物组合物，以及用于预防与治疗癌症和与血管生成相关疾病的用途和方法。
• Synthesis and in Vitro and in Vivo Anticoagulant and Antiplatelet Activities of Amidino- and Non-Amidinobenzamides
  作者：Soo Lee、Wonhwa Lee、Jong-Sup Bae、Eunsook Ma

  DOI：10.3390/molecules21050676

  日期：——

  mino) benzamide (2, 43.5 ± 0.6 s) were selected to investigate the further anticoagulant and antiplatelet activities. The aPTT results of 1 (33.2 ± 0.7 s) and 2 (43.5 ± 0.6 s) were compared with heparin (62.5 ± 0.8 s) in vitro at 30 μM. We investigated the effect of 1 and 2 on blood anticoagulant activity (ex vivo) and on tail bleeding time (in vivo) on mice. A tail cutting/bleeding time assay revealed

  合成了三种脒基和十种非脒基苯甲酰胺，作为基于 3-氨基苯甲酸支架的抗凝剂和抗血小板化合物。通过筛选体外活化部分凝血活酶时间 (aPTT) 和凝血酶原时间 (PT) 的延长，初步评估了 13 种合成化合物 1-13、2b 和 3b 作为前药的抗凝活性。从获得的 aPTT 结果，两种脒基苯甲酰胺，N-(3'-脒基苯基)-3-(噻吩-2''-基羰基氨基)苯甲酰胺 (1, 33.2 ± 0.7 s) 和 N-(4'-脒基苯基)-3-选择 (噻吩-2''-基羰基氨基) 苯甲酰胺 (2, 43.5 ± 0.6 s) 来研究进一步的抗凝和抗血小板活性。1 (33.2 ± 0.7 s) 和 2 (43.5 ± 0.6 s) 的 aPTT 结果与体外 30 μM 的肝素 (62.5 ± 0.8 s) 进行了比较。我们研究了 1 和 2 对小鼠血液抗凝活性（离体）和尾部出血时间（体内）的影响。切尾/流血时间测定表明，1